Best Practice & Research Clinical Haematology

Papers
(The median citation count of Best Practice & Research Clinical Haematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation67
The role of randomized controlled trials, registries, observational databases in evaluating new interventions24
Contemporary and future strategies in polycythemia vera24
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes21
Endpoint selection and evaluation in hematology studies21
Coagulopathy in COVID-19 and anticoagulation clinical trials19
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL19
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances18
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)18
Editorial Board17
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program17
Take a spin: Apheresis in the care of adult leukaemia patients15
Vaccine-induced immune thrombotic thrombocytopenia14
Targeted cellular therapy for treatment of relapsed or refractory leukemia14
The presentation of results from studies in clinical haematology14
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma13
Accelerated and blast phase myeloproliferative neoplasms12
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”10
Blood coagulation and cancer genes10
Principles of cost-effectiveness studies and their use in haematology10
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms10
Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma10
Creating a GMP cell processing program: A focus on quality and regulation10
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults10
The international cooperative Gaucher group (ICCG) Gaucher registry9
What should be done and what should be avoided when comparing two treatments?9
Cancer associated thrombosis in pediatric patients9
Dysregulation of Protein S in COVID-198
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma7
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration7
Editorial Board7
Corrigendum to “Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)” [Best Pract Res Clin Haematol 38 2 2025]7
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders7
The role of registries in hematological disorders7
Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation7
Addressing symptom burden in myeloproliferative neoplasms7
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?7
Anti-GM-CSF autoantibodies in myeloid leukemias6
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies6
Thrombosis and bleeding in hematological malignancy6
Challenges in anticoagulation for patients with brain tumors6
How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?6
Handling missing covariate data in clinical studies in haematology6
A reflection on Arnold Caplan, the father of MSC6
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment6
Recent progress in acute leukemia and myelodysplasia5
CAR assembly line: Taking CAR T-cell manufacturing to the next level5
Editorial Board / Aims & Scope5
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia5
Advances in polycythemia vera and lessons for acute leukemia5
Cytogenetics and genomics in CML and other myeloproliferative neoplasms5
What is the role of the bone marrow microenvironment in AML?5
Cytokines in hematopoietic cell transplantation and related cellular therapies5
The most frequent HLA alleles around the world: A fundamental synopsis5
What is relative survival and what is its role in haematology?4
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care4
CARs for lymphoma4
When to use which molecular prognostic scoring system in the management of patients with MDS?4
Corrigendum to “Designing and conducting a clinical trial in blood and marrow transplantation” [Best Pract Res Clin Haematol 36 (2023) 101471]4
Preface4
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia4
Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation4
Therapeutic initiatives using mesenchymal stem cells and other novel cells in hematology4
Corrigendum to “Endpoint selection and evaluation in hematology studies” [Best Pract Res Clin Haematol 36 (2023) 101479]4
Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation4
Preface of special edition “Biostatistics in clinical haematology”4
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents3
Since everyone has a donor, why are some eligible patients still not transplanted?3
Cytokine therapy of acute radiation syndrome3
Donor lymphocyte infusion in Acute Myeloid Leukemia3
The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-193
Editorial Board / Aims & Scope3
Diagnosis and management of rare paediatric Non-Hodgkin lymphoma3
Considerations to comprehensive care for the older individual with myelofibrosis3
COVID-19 and antiphospholipid antibodies3
Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy3
Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults3
Editorial Board2
Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders2
The Collaborative Biobank (CoBi): Donor and recipient samples & data to facilitate future research on hematopoietic cell transplantation2
Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL)2
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry2
Thromboprophylaxis of cancer patients undergoing systemic therapy in the ambulatory setting2
Advancing MSC therapy: The next generation of potent mesenchymal stromal cells for systemic autoimmune rheumatic diseases2
Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults2
Editorial Board2
COVID-19: A hematological perspective2
Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse2
Editorial Board / Aims & Scope2
Is there an optimal adjunct therapy to traditional cytotoxic induction?2
Using real-world evidence in haematology2
Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia2
Designing and conducting a clinical trial in blood and marrow transplantation2
Natural born Killers: Harnessing NK cells to treat cancer2
Redox stress in COVID-19: Implications for hematologic disorders2
The best GVHD prophylaxis: Or at least progress towards finding it2
Cytokines in transplantation tolerance2
Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?2
Mesenchymal stem cells in hematology: Therapeutic initiatives and future directions2
Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia2
Consolidation chemotherapy in AML: Are we playing with a full deck of cards?2
HLA-DM and HLA-DO interplay for the peptide editing of HLA class II in healthy tissues and leukemia2
Myeloproliferative neoplasms in adolescents and young adults2
Cytogenetics and genomics in pediatric acute lymphoblastic leukaemia2
Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?2
0.08345103263855